alpha-FMH
Phase 1Small molecule
alpha-FMH is one of 11 small molecule programs targeting Exercise. It is currently in Phase 1.
1
Indications
1
Total Trials
1
Active Trials
10
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
12 competitors in Exercise
#DrugCompanyPhaseTrials
1Mounjaro
Eli LillyPhase 3
Lipitor
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Phase 3
Cialis
Eli LillyPhase 2
Zesly
MMezzion Pharma Co. Ltd
Phase 3
HS-20094
Jiangsu Hansoh Pharmaceutical Co., Ltd.Phase 3
Intropin
PfizerPreclinical
Antihistamine
Arrowhead PharmaceuticalsPhase 1
Reglan
IIstituto Clinico Humanitas
Preclinical
BAY987517
BayerPreclinical
Sildenafil ODT
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for alpha-FMH. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 1[1]
- Company
- UUniversity of Oregon